Cure My Disease

Don't miss your cure!

 Log in / Sign up

New combo attack on tough pancreatic cancer shows promise in early trial

NCT ID NCT02481635

Disease control Sponsor: University Health Network, Toronto Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed This study
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 27, 2026 · Last updated Jul 10, 2026 · Updated 1 time

Summary

This study tests a treatment plan for people with advanced pancreatic cancer that has spread to a major artery. Participants receive chemotherapy and radiation before surgery, then more chemo after. The goal is to see if this approach is safe and helps patients live longer. The trial involves 30 adults under 70 who are healthy enough for major surgery.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Phase 1/2

Runs two stages together: safety and dose first, then whether the treatment works.

Participants

11 people

The number who actually took part.

Started

Dec 2016

Finished

Dec 2024

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

18 to 70 years

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: Surgical: * Medically fit for major pancreatic surgery * No evidence of metastases * No prior resection * Arterial involvement limited to a single major vessel and is resectable * Tumour-free margins could be achieved * Acceptable length of vessel * Mass considered otherwise resectable by current standards General: * Less than 70 years old * Performance status \<=2 * Has pancreatic adenocarcinoma * Adequate bone marrow and organ function * Therapeutic heparin is allowed * Taking chronic erythropoietin are permitted * Not pregnant * Agree to use contraception * Able to provide written consent Exclusion Criteria: Surgical: * Aortic involvement * Involvement of 2 major arterial trunks * SMV/portal venous occlusion, cannot be reconstructed * Extensive venous involvement, no arterial involvement * Disease progression on neo-adjuvant treatme General: * Concurrent cancer diagnosis * Other malignancies unless all therapy completed, no disease for \>=3 years * Prior radiotherapy or chemo within 1 year, to pancreas * Bone marrow transplant/stem cell rescue * Major surgery \<4 wks prior * Distant metastases * Renal dysfunction * Pulmonary insufficiency * History of cardiac disease * Active systemic infection(s) or any other related illnesses * Known HIV, HBV, HCV * History of solid organ transplant, cardiovascular disease, inflammatory bowel disease, or underlying neuropathy * Conditions interfering with patient participation * Known or suspected allergy to study drugs * Pregnant or breast-feeding * Therapeutic coumadin * More than or equal to Grade 2 pre-exiting peripheral neuropathy

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Pancreatic adenocarcinoma are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

malignant pancreatic neoplasm pancreatic adenocarcinoma pancreatic neoplasm

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Pancreatic cancer

Contacts and locations

Locations

  • Princess Margaret Cancer Centre

    Toronto, Ontario, M5G 2M9, Canada

More trials for these conditions

Other studies related to the condition(s) this trial covers.